面肌痉挛微血管减压术后生活质量改善的研究
这项回顾性研究结合系统综述与Meta分析,评估面肌痉挛患者接受微血管减压术(MVD)和肉毒毒素(BT)治疗后的生活质量(QOL)。回顾性分析中,331例中242例完成问卷,MVD术后10项QOL问题平均分从22.78(标准差9.83)降至2.17(标准差5.75)(p<0.001),各分量表均显著改善。系统综述报告约90%的MVD患者症状完全恢复,而BT治疗平均峰值改善为77%。
要点
- MVD术后10项QOL问题平均分从22.78降至2.17(p<0.001),各分量表均显著改善。
- 系统综述报告约90%的MVD患者症状完全恢复,BT治疗平均峰值改善为77%。
- MVD患者报告的平均补充QOL指数改善大于接受BT治疗的患者。
核心结论
- 微血管减压术可显著改善经过良好选择的面肌痉挛患者的生活质量,且可能较肉毒毒素注射带来更大的生活质量获益。
研究设计与样本
- 回顾性研究结合系统综述与Meta分析,回顾性分析纳入由单一术者行MVD的所有患者并发放生活质量问卷,问卷包括基于作者经验开发的问题及健康相关生活质量HFS-8问卷;系统综述检索英文文献报告MVD或BT治疗面肌痉挛的结局和并发症。
主要发现
- 回顾性分析中331例患者有242例完成问卷,MVD术后10项QOL问题平均分从22.78(标准差9.83)改善至2.17(标准差5.75)(p<0.001)。
- 问卷所有分量表在术前与术后回答之间均有显著改善(p<0.001)。
- 系统综述报告约90%的MVD患者症状完全恢复,而BT治疗的平均峰值症状改善为77%。
- MVD患者报告的平均补充QOL指数改善大于接受BT治疗的患者。
临床怎么用
- 作者认为,微血管减压术可显著改善经过良好选择的面肌痉挛患者的生活质量,且可能较肉毒毒素注射带来更大的生活质量获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE Hemifacial spasm (HFS) is a movement disorder characterized by involuntary spasms of the facial muscles, and it can negatively impact quality of life (QOL). This retrospective study and systematic review with meta-analysis was conducted to investigate the QOL in patients with HFS following intervention with microvascular decompression (MVD) and botulinum toxin (BT). METHODS In the retrospective analysis, a QOL questionnaire was administered to all patients undergoing MVD performed by a single surgeon. The QOL questionnaire included unique questions developed based on the authors' experience with HFS patients in addition to the health-related QOL HFS-8 questionnaire. The authors also report on a systematic review of the English literature providing outcomes and complications in patients with HFS undergoing treatment with either MVD or BT. RESULTS Regarding the retrospective analysis, 242 of 331 patients completed the questionnaire. The mean score of the 10 QOL questions improved from 22.78 (SD 9.83) to 2.17 (SD 5.75) following MVD (p < 0.001). There was significant improvement across all subscales of the questionnaire between pre- and postoperative responses (p < 0.001). Regarding the systematic review, it is reported that approximately 90% of patients undergoing MVD for HFS experience a complete recovery from symptoms, whereas the mean peak improvement of symptoms following treatment with BT is 77%. Furthermore, patients undergoing MVD reported a greater improvement in the mean supplemental index of QOL as compared with patients receiving BT therapy. CONCLUSIONS Microvascular decompression offers a significant improvement in QOL in well-selected patients suffering from HFS, and may offer an increased benefit for QOL over BT injections.
引用
- Lawrence JD, Frederickson AM, Chang YF, et al. An investigation into quality of life improvement in patients undergoing microvascular decompression for hemifacial spasm. J Neurosurg. 2017. PMID: 28186450. doi:10.3171/2016.9.JNS161022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。